Claim 16: The cysteine engineered antibody of claim 15, wherein the antibody comprises the sequence selected from SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, and SEQ ID NO:259.

Claim 17: The cysteine engineered antibody of any one of claims 14-16, wherein the one or more free cysteine amino acid residues located in a heavy chain comprise a free cysteine amino acid at position 118 of the heavy chain according to EU numbering convention.

Claim 18: The cysteine engineered antibody of claim 17, wherein the antibody comprises the sequence of SEQ ID NO:255.

Claim 19: The cysteine engineered antibody of any one of claims 14-18, wherein the one or more free cysteine amino acid residues located in a heavy chain comprise a free cysteine amino acid at position 400 of the heavy chain according to EU numbering convention.

Claim 20: The cysteine engineered antibody of claim 19, wherein the antibody comprises the sequence of SEQ ID NO:259.

Claim 21: The cysteine engineered antibody of claim 1, wherein the antibody comprises a light chain comprising the sequence of SEQ ID NO:231 and a heavy chain comprising the sequence of SEQ ID NO:230.

Claim 22: The cysteine engineered antibody of claim 1, wherein the antibody comprises a light chain comprising the sequence of SEQ ID NO:233 and a heavy chain comprising the sequence of SEQ ID NO:232.

Claim 23: The cysteine engineered antibody of any one of claims 1-22, wherein the antibody is selected from a monoclonal antibody, a bispecific antibody, a chimeric antibody, a human antibody, and a humanized antibody.

Claim 24: The cysteine engineered antibody of any one of claims 1-23, wherein the antibody is ~~an antibody fragment~~.

Claim 56: Use of the antibody of any one of claims 1-25 or immunoconjugate of any one of claims 41-54 in the preparation of a medicament for inhibiting the growth of a cell that expresses CD79b.

Claim 57: The use of claim 56, wherein the medicament further comprises an effective amount of another therapeutic agent.

Claim 58: Use of the antibody of any of claims 1-25 or an immunoconjugate of any one of claims 41-54 in the preparation of a medicament for treating a proliferative disorder.

Claim 59: The use of claim 58, wherein said proliferative disorder is cancer.

Claim 60: The use of claim 59, wherein said cancer is selected from lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

Claim 61: The use of any one of claims 58-60, wherein the medicament further comprises an effective amount of another therapeutic agent.

Claim 62: The use of claim 61, wherein the therapeutic agent is selected from the group consisting of an antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, a cancer vaccine, or a growth-inhibitory agent.

Claim 63: The use of claim 61, wherein the therapeutic agent is selected from the group consisting of velcade, revlimid, tamoxifen, letrozole, exemestane, anastrozole, irinotecan, cetuximab, fulvestrant, vinorelbine, erlotinib, bevacizumab, vincristine, imatinib,

sorafenib, lapatinib, or trastuzumab, cisplatin, gemcitabine, methotrexate, vinblastine, carboplatin, paclitaxel, pemetrexed, 5-fluorouracil, doxorubicin, bortezomib, lenalidomide, melphalin, prednisone, dexamethasone, or docetaxel.

Claim 64: The use of claim 61, wherein the therapeutic agent is an anti-CD20 antibody.

Claim 65: The use of claim 61 or 64, further comprising one or more of cyclophosphamide, hydroxydaunorubicin, adriamycin, and doxorubincin.

Claim 66: An in vitro method of determining the presence of CD79b in a biological sample suspected of containing CD79b, said method comprising in vitro exposing said sample to the antibody claim 1-25, and determining binding of said antibody to CD79b in said sample wherein binding of said antibody to CD79b in said sample is indicative of the presence of said protein in said sample.

Claim 67: A method for making an antibody drug conjugate compound comprising the anti-CD79b antibody (Ab) of any one of claims 1-25, and an auristatin or maytansinoid drug moiety (D) wherein the antibody is attached through the one or more cysteine amino acids by a linker moiety (L) to D; the compound having Formula I:

$$Ab-(L-D)_p \qquad I$$

where p is 1, 2, 3, or 4; the method comprising the steps of:

(a) reacting an engineered cysteine group of the antibody with a linker reagent to form antibody-linker intermediate Ab-L; and

(b) reacting Ab-L with an activated drug moiety D; whereby the antibody-drug conjugate is formed;

or comprising the steps of:

(c) reacting a nucleophilic group of a drug moiety with a linker reagent to form drug-linker intermediate D-L; and

(d) reacting D-L with an engineered cysteine group of the antibody; whereby the antibody-drug conjugate is formed.

Claim 68: The method of claim 67, further comprising the step of expressing the antibody in Chinese hamster ovary (CHO) cells.

Claim 69: The method of any one of claims 67-68, further comprising the step of treating the expressed antibody with a reducing agent.

Claim 70: The method of claim 69, wherein the reducing agent is selected from TCEP and DTT.

Claim 71: The method of any one of claims 69-70, further comprising the step of treating the expressed antibody with an oxidizing agent, after treating with the reducing agent.

Claim 72: The method of claim 71, wherein the oxidizing agent is selected from copper sulfate, dehydroascorbic acid, and air.

Claim 73: An immunoconjugate comprising a cysteine engineered monoclonal anti-CD79b antibody comprising:

(a) a light chain variable domain comprising:

i. HVR-L1 comprising the amino acid sequence of SEQ ID NO: 194;

ii. HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and

iii. HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

(b) a heavy chain variable domain comprising:

i. HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

ii. HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

iii. HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

which antibody is covalently attached to a therapeutic agent through the free cysteine amino acid.

Claim 74: An immunoconjugate comprising a cysteine engineered monoclonal anti-CD79b antibody comprising:

(a) a light chain variable domain comprising:

i. HVR-L1 comprising the amino acid sequence of SEQ ID NO: 131;

ii. HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and

iii. HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

(b) a heavy chain variable domain comprising:

i. HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

ii. HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

iii. HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

which antibody is covalently attached to a therapeutic agent through the free cysteine amino acid.

Claim 75: An immunoconjugate having the formula Ab-(L-D)p, wherein:

(a) Ab is a cysteine engineered antibody, wherein the antibody is an isolated monoclonal anti-CD79b antibody comprising:

i. a light chain variable domain comprising:

a. HVR-L1 comprising the amino acid sequence of SEQ ID NO: 194;

b. HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and

c. HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

ii. a heavy chain variable domain comprising:

a. HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

b. HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

c. HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

(b) L is a linker moiety which links Ab to D through the free cysteine amino acid, and wherein the linker is MC-VC-PAB;

(c) D is a drug moiety, wherein the drug moiety is MMAE; and

(d) p is 1 to 8.

Claim 76: The immunoconjugate of claim 75, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 208 and the light chain variable domain comprises amino acid sequence of SEQ ID NO:207.

Claim 77: The immunoconjugate of claim 75, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 233 and the light chain comprises amino acid sequence of SEQ ID NO:232.

Claim 78: An immunoconjugate having the formula Ab-(L-D)p, wherein:

(a) Ab is a cysteine engineered antibody, wherein the antibody is an isolated monoclonal anti-CD79b antibody comprising:

i. a light chain variable domain comprising:

a. HVR-L1 comprising the amino acid sequence of SEQ ID NO: 131;

b. HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and

c. HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

ii. a heavy chain variable domain comprising:

a. HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

b. HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

c. HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

(b) L is a linker moiety which links Ab to D through the free cysteine amino acid, and wherein the linker is MC-VC-PAB;

(c) D is a drug moiety, wherein the drug moiety is MMAE; and

(d) p is 1 to 8.

Claim 79: The immunoconjugate of claim 78, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 189 and the light chain variable domain comprises amino acid sequence of SEQ ID NO: 188.

Claim 80: The immunoconjugate of claim 78, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 231 and the light chain comprises amino acid sequence of SEQ ID NO: 230.

Claim 16: The cysteine engineered antibody of claim 15, wherein the antibody comprises the sequence selected from SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, SEQ ID NO:258, and SEQ ID NO:259.

Claim 17: The cysteine engineered antibody of any one of claims 14-16, wherein the one or more free cysteine amino acid residues located in a heavy chain comprise a free cysteine amino acid at position 118 of the heavy chain according to EU numbering convention.

Claim 18: The cysteine engineered antibody of claim 17, wherein the antibody comprises the sequence of SEQ ID NO:255.

Claim 19: The cysteine engineered antibody of any one of claims 14-18, wherein the one or more free cysteine amino acid residues located in a heavy chain comprise a free cysteine amino acid at position 400 of the heavy chain according to EU numbering convention.

Claim 20: The cysteine engineered antibody of claim 19, wherein the antibody comprises the sequence of SEQ ID NO:259.

Claim 21: The cysteine engineered antibody of claim 1, wherein the antibody comprises a light chain comprising the sequence of SEQ ID NO:231 and a heavy chain comprising the sequence of SEQ ID NO:230.

Claim 22: The cysteine engineered antibody of claim 1, wherein the antibody comprises a light chain comprising the sequence of SEQ ID NO:233 and a heavy chain comprising the sequence of SEQ ID NO:232.

Claim 23: The cysteine engineered antibody of any one of claims 1-22, wherein the antibody is selected from a monoclonal antibody, a bispecific antibody, a chimeric antibody, a human antibody, and a humanized antibody.

Claim 24: The cysteine engineered antibody of any one of claims 1-23, wherein the antibody is an antigen binding fragments.

Claim 56: Use of the antibody of any of claims 1-25 or an immunoconjugate of any one of claims 41-54 in the preparation of a medicament for treating a proliferative disorder, wherein said proliferative disorder is cancer.

Claim 57: The use of claim 56, wherein said cancer is selected from lymphoma, non-Hodgkins lymphoma (NHL), aggressive NHL, relapsed aggressive NHL, relapsed indolent NHL, refractory NHL, refractory indolent NHL, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, leukemia, hairy cell leukemia (HCL), acute lymphocytic leukemia (ALL), and mantle cell lymphoma.

Claim 58: The use of any one of claims 56-57, wherein the medicament further comprises an effective amount of another therapeutic agent.

Claim 59: The use of claim 58, wherein the therapeutic agent is selected from the group consisting of an antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, a cancer vaccine, or a growth-inhibitory agent.

Claim 60: The use of claim 58, wherein the therapeutic agent is selected from the group consisting of velcade, revlimid, tamoxifen, letrozole, exemestane, anastrozole, irinotecan, cetuximab, fulvestrant, vinorelbine, erlotinib, bevacizumab, vincristine, imatinib, sorafenib, lapatinib, or trastuzumab, cisplatin, gemcitabine, methotrexate, vinblastine, carboplatin, paclitaxel, pemetrexed, 5-fluorouracil, doxorubicin, bortezomib, lenalidomide, melphalin, prednisone, dexamethasone, or docetaxel.

Claim 61: The use of claim 58, wherein the therapeutic agent is an anti-CD20 antibody.

Claim 62: The use of claim 58 or 61, further comprising one or more of cyclophosphamide, hydroxydaunorubicin, adriamycin, and doxorubincin.

Claim 63: An in vitro method of determining the presence of CD79b in a biological sample suspected of containing CD79b, said method comprising in vitro exposing said sample to the antibody claim 1-25, and determining binding of said antibody to CD79b in said sample wherein binding of said antibody to CD79b in said sample is indicative of the presence of said protein in said sample.

Claim 64: A method for making an antibody drug conjugate compound comprising the anti-CD79b antibody (Ab) of any one of claims 1-25, and an auristatin or maytansinoid drug moiety (D) wherein the antibody is attached through the one or more cysteine amino acids by a linker moiety (L) to D; the compound having Formula I:

$$Ab–(L–D)_p \qquad I$$

where p is 1, 2, 3, or 4; the method comprising the steps of:

(a) reacting an engineered cysteine group of the antibody with a linker reagent to form antibody-linker intermediate Ab-L; and

(b) reacting Ab-L with an activated drug moiety D; whereby the antibody-drug conjugate is formed;

or comprising the steps of:

(c) reacting a nucleophilic group of a drug moiety with a linker reagent to form drug-linker intermediate D-L; and

(d) reacting D-L with an engineered cysteine group of the antibody; whereby the antibody- drug conjugate is formed.

Claim 65: The method of claim 64, further comprising the step of expressing the antibody in Chinese hamster ovary (CHO) cells.

Claim 66: The method of any one of claims 63-65, further comprising the step of treating the expressed antibody with a reducing agent.

Claim 67: The method of claim 66, wherein the reducing agent is selected from TCEP and DTT.

Claim 68: The method of any one of claims 66-67, further comprising the step of treating the expressed antibody with an oxidizing agent, after treating with the reducing agent.

Claim 69: The method of claim 68, wherein the oxidizing agent is selected from copper sulfate, dehydroascorbic acid, and air.

Claim 70: An immunoconjugate comprising a cysteine engineered monoclonal anti-CD79b antibody comprising:

(a) a light chain variable domain comprising:
    (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 194;
    (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and
    (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and
(b) a heavy chain variable domain comprising:
    (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;
    (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and
    (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

which antibody is covalently attached to a therapeutic agent through the free cysteine amino acid.

Claim 71: An immunoconjugate comprising a cysteine engineered monoclonal anti-CD79b antibody comprising:

(a) a light chain variable domain comprising:
    (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 131;
    (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and
    (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

(b) a heavy chain variable domain comprising:

(i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

(ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

(iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138; which antibody is covalently attached to a therapeutic agent through the free cysteine amino acid.

Claim 72: An immunoconjugate having the formula Ab-(L-D)p, wherein:

(a) Ab is a cysteine engineered antibody, wherein the antibody is an isolated monoclonal anti-CD79b antibody comprising:

(i) a light chain variable domain comprising:

a. HVR-L1 comprising the amino acid sequence of SEQ ID NO: 194;

b. HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and

c. HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

(ii) a heavy chain variable domain comprising:

a. HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

b. HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

c. HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

(b) L is a linker moiety which links Ab to D through the free cysteine amino acid, and

wherein the linker is MC-VC-PAB;

(c) D is a drug moiety, wherein the drug moiety is MMAE; and

(d) p is 1 to 8.

Claim 73: The immunoconjugate of claim 72, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 208 and the light chain variable

domain comprises amino acid sequence of SEQ ID NO: 207.

Claim 74: The immunoconjugate of claim 72, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 233 and the heavy chain comprises amino acid sequence of SEQ ID NO: 232.

Claim 75: An immunoconjugate having the formula Ab-(L-D)p, wherein:

(a) Ab is a cysteine engineered antibody, wherein the antibody is an isolated monoclonal anti-CD79b antibody comprising:

(i) a light chain variable domain comprising:

a. HVR-L1 comprising the amino acid sequence of SEQ ID NO: 131;

b. HVR-L2 comprising the amino acid sequence of SEQ ID NO: 132; and

c. HVR-L3 comprising the amino acid sequence of SEQ ID NO: 133; and

(ii) a heavy chain variable domain comprising:

a. HVR-H1 comprising the amino acid sequence of SEQ ID NO: 134;

b. HVR-H2 comprising the amino acid sequence of SEQ ID NO: 135; and

c. HVR-H3 comprising the amino acid sequence of SEQ ID NO: 138;

(b) L is a linker moiety which links Ab to D through the free cysteine amino acid, and wherein the linker is MC-VC-PAB;

(c) D is a drug moiety, wherein the drug moiety is MMAE; and

(d) p is 1 to 8.

Claim 76: The immunoconjugate of claim 75, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 189 and the light chain variable domain comprises amino acid sequence of SEQ ID NO: 188.

Claim 77: The immunoconjugate of claim 75, wherein the light chain comprises the amino acid sequence of SEQ ID NO: 231 and the heavy chain comprises amino acid sequence of SEQ ID NO: 230.